The COVID-19 pandemic led to a steep, transient decline in market value in 2020 (sales of $4.2bn versus $6.4bn in 2019) as new patient initiations dropped due to disrupted screening initiatives and difficulty in accessing physician care, particularly in patients with less advanced fibrosis where treatment can be delayed without risking negative outcomes. In 2021, sales fell further due to ongoing disruptions during the pandemic; however, the market was transiently boosted in 2022 as warehoused patients were treated. Looking to 2023 and beyond, the market will contract in a stepwise fashion due to a depleting patient pool as the rate that patients are treated vastly outpaces the number of newly diagnosed patients. 

The current treatment paradigm is dominated by two competing pan-genotypic regimens, Epclusa and Mavyret, which possess excellent efficacy (cure rates of ≥95%), strong tolerability profiles (≤1% of patients discontinue due to adverse events), and convenient once-daily dosing schedules with treatment durations of 8–12 weeks. 

This Datamonitor Healthcare report contains a Disease Analysis module.